Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $101.0 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $101.0 million, down 9.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.0 million (down 9.3% YoY), and the FY2025 annual result was $107.6 million, down 9.44% from the prior year.
• Total Non-Current Liabilities came in at $101.0 million for Q1 2026 at Allogene Therapeutics, down from $107.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $152.9 million in Q1 2023 to a low of $101.0 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $119.8 million (2024), against an average of $124.4 million.
• Across the five-year window, Total Non-Current Liabilities surged 46.5% in 2022 and decreased 21.65% in 2024, its largest moves.
• Allogene Therapeutics' Total Non-Current Liabilities stood at $148.8 million in 2022, then retreated by 15.74% to $125.4 million in 2023, then fell by 5.31% to $118.8 million in 2024, then declined by 9.44% to $107.6 million in 2025, then dropped by 6.13% to $101.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $101.0 million (Q1 2026), $107.6 million (Q4 2025), and $109.0 million (Q3 2025), per Business Quant data.